WO2002014358A3 - Novel secreted proteins and their uses - Google Patents

Novel secreted proteins and their uses Download PDF

Info

Publication number
WO2002014358A3
WO2002014358A3 PCT/US2001/021124 US0121124W WO0214358A3 WO 2002014358 A3 WO2002014358 A3 WO 2002014358A3 US 0121124 W US0121124 W US 0121124W WO 0214358 A3 WO0214358 A3 WO 0214358A3
Authority
WO
WIPO (PCT)
Prior art keywords
secreted proteins
novel secreted
useful
nucleic acids
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/021124
Other languages
French (fr)
Other versions
WO2002014358A2 (en
Inventor
Brian Taylor Edmonds
Radmila Micanovic
Weijia Ou
Eric Wen Su
Sheng-Hung Rainbow Tschang
He Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to US10/343,348 priority Critical patent/US20040038242A1/en
Priority to EP01958861A priority patent/EP1309614A2/en
Priority to AU2001280471A priority patent/AU2001280471A1/en
Publication of WO2002014358A2 publication Critical patent/WO2002014358A2/en
Anticipated expiration legal-status Critical
Publication of WO2002014358A3 publication Critical patent/WO2002014358A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention provides nucleic acid sequences encoding novel human proteins. These novel nucleic acids are useful for constructing the claimed DNA vectors and host cells of the invention and for preparing the claimed nucleic acids, recombinant proteins and antibodies that are useful in the claimed methods and medical uses.
PCT/US2001/021124 2000-08-11 2001-07-30 Novel secreted proteins and their uses Ceased WO2002014358A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/343,348 US20040038242A1 (en) 2001-07-30 2001-07-30 Novel secreted proteins and their uses
EP01958861A EP1309614A2 (en) 2000-08-11 2001-07-30 Novel secreted proteins and their uses
AU2001280471A AU2001280471A1 (en) 2000-08-11 2001-07-30 Novel secreted proteins and their uses

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22464200P 2000-08-11 2000-08-11
US60/224,642 2000-08-11
US24177900P 2000-10-19 2000-10-19
US60/241,779 2000-10-19

Publications (2)

Publication Number Publication Date
WO2002014358A2 WO2002014358A2 (en) 2002-02-21
WO2002014358A3 true WO2002014358A3 (en) 2003-03-13

Family

ID=26918895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/021124 Ceased WO2002014358A2 (en) 2000-08-11 2001-07-30 Novel secreted proteins and their uses

Country Status (3)

Country Link
EP (1) EP1309614A2 (en)
AU (1) AU2001280471A1 (en)
WO (1) WO2002014358A2 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008332B2 (en) 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
US8124617B2 (en) 2005-09-01 2012-02-28 Takeda San Diego, Inc. Imidazopyridine compounds
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
US8859741B2 (en) 2007-08-23 2014-10-14 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8999341B1 (en) 2014-07-15 2015-04-07 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9062105B1 (en) 2014-07-15 2015-06-23 Kymab Limited Precision Medicine by targeting VEGF-A variants for treatment of retinopathy
US9109034B1 (en) 2014-07-15 2015-08-18 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9266961B2 (en) 2012-06-15 2016-02-23 Genentech, Inc. Anti-PCSK9 antibodies, formulations, dosing, and methods of use

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1255771A4 (en) * 2000-02-14 2004-09-29 Smithkline Beecham Corp Novel compounds
CA2429179A1 (en) 2000-11-14 2002-06-23 Bristol-Myers Squibb Company Polynucleotide encoding a novel human serpin secreted from lymphoid cells lsi-01
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2008063382A2 (en) 2006-11-07 2008-05-29 Merck & Co., Inc. Antagonists of pcsk9
WO2008118386A2 (en) 2007-03-27 2008-10-02 Merck & Co., Inc. Method for detecting autoprocessed, secreted pcsk9
AR070315A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
AR070316A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
AU2010313324A1 (en) 2009-10-30 2012-04-12 Merck Sharp & Dohme Corp. AX213 and AX132 PCSK9 antagonists and variants
US8802827B2 (en) 2009-10-30 2014-08-12 Merck Sharp & Dohme Corp. AX1 PCSK9 antagonists
RS62387B1 (en) 2010-01-29 2021-10-29 Chugai Pharmaceutical Co Ltd Anti-dll3 antibody
JOP20200043A1 (en) 2011-05-10 2017-06-16 Amgen Inc Ways to treat or prevent cholesterol disorders
AR087715A1 (en) 2011-09-16 2014-04-09 Lilly Co Eli ANTI PCSK9 ANTIBODIES AND USES OF THE SAME
CA2865404C (en) 2012-02-24 2019-08-27 Stem Centrx, Inc. Dll3-binding antibodies and drug conjugates thereof to treat cancer
MX2015010682A (en) 2013-02-22 2016-05-31 Stemcentrx Inc Novel antibody conjugates and uses thereof.
JP2016531915A (en) 2013-08-28 2016-10-13 ステムセントリックス， インコーポレイテッド Site-specific antibody conjugation methods and compositions
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
WO2015127407A1 (en) 2014-02-21 2015-08-27 Stemcentrx, Inc. Anti-dll3 antibodies and drug conjugates for use in melanoma
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR102379464B1 (en) 2016-06-20 2022-03-29 키맵 리미티드 anti-PD-L1 antibody
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018119354A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Gene editing of pcsk9
TWI817974B (en) 2017-12-28 2023-10-11 日商中外製藥股份有限公司 Cytotoxicity-inducing therapeutic agent
IL296803A (en) 2020-03-31 2022-11-01 Chugai Pharmaceutical Co Ltd Dll3-targeting multispecific antigen-binding molecules and uses thereof
BR112022020428A2 (en) 2020-04-09 2023-03-07 Verve Therapeutics Inc BASE EDITION OF ANGPTL3 AND METHODS OF USE FOR THE TREATMENT OF DISEASES

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006443A1 (en) * 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor, lefty-2
WO1999009198A1 (en) * 1997-08-21 1999-02-25 Human Genome Sciences, Inc. Human nodal and lefty homologues
WO1999029718A2 (en) * 1997-12-10 1999-06-17 Genetics Institute, Inc. Bone morphogenetic protein (bmp)-17 and bmp-18 and compositions thereof
US5916751A (en) * 1996-08-27 1999-06-29 University Of South Florida Method for the diagnosis of selected adenocarcinomas
WO2000066068A2 (en) * 1999-04-29 2000-11-09 North Shore Long Island Jewish Research Corporation Method for inducing growth and enhancing survival of nervous tissue

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916751A (en) * 1996-08-27 1999-06-29 University Of South Florida Method for the diagnosis of selected adenocarcinomas
WO1999006443A1 (en) * 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor, lefty-2
WO1999009198A1 (en) * 1997-08-21 1999-02-25 Human Genome Sciences, Inc. Human nodal and lefty homologues
WO1999029718A2 (en) * 1997-12-10 1999-06-17 Genetics Institute, Inc. Bone morphogenetic protein (bmp)-17 and bmp-18 and compositions thereof
WO2000066068A2 (en) * 1999-04-29 2000-11-09 North Shore Long Island Jewish Research Corporation Method for inducing growth and enhancing survival of nervous tissue

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOSAKI K ET AL: "Characterization and mutation analysis of human LEFTY A and LEFTY B, homologues of murine genes implicated in left-right axis development.", AMERICAN JOURNAL OF HUMAN GENETICS, vol. 64, no. 3, March 1999 (1999-03-01), pages 712 - 721, XP002210149, ISSN: 0002-9297 *

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124617B2 (en) 2005-09-01 2012-02-28 Takeda San Diego, Inc. Imidazopyridine compounds
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
US8008332B2 (en) 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
US8394843B2 (en) 2006-05-31 2013-03-12 Takeda California, Inc. Substituted isoindoles as glucokinase activators
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
US8859741B2 (en) 2007-08-23 2014-10-14 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8871913B2 (en) 2007-08-23 2014-10-28 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8871914B2 (en) 2007-08-23 2014-10-28 Amgen, Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8883983B2 (en) 2007-08-23 2014-11-11 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8889834B2 (en) 2007-08-23 2014-11-18 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US9493576B2 (en) 2007-08-23 2016-11-15 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8981064B2 (en) 2007-08-23 2015-03-17 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US9266961B2 (en) 2012-06-15 2016-02-23 Genentech, Inc. Anti-PCSK9 antibodies, formulations, dosing, and methods of use
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9109034B1 (en) 2014-07-15 2015-08-18 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8999341B1 (en) 2014-07-15 2015-04-07 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034331B1 (en) 2014-07-15 2015-05-19 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9062105B1 (en) 2014-07-15 2015-06-23 Kymab Limited Precision Medicine by targeting VEGF-A variants for treatment of retinopathy
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9187562B1 (en) 2014-07-15 2015-11-17 Kymab Limited Methods for treating anaemia
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9303089B2 (en) 2014-07-15 2016-04-05 Kymab Limited Methods of treating anaemia
US9394568B2 (en) 2014-07-15 2016-07-19 Kymab Limited Methods of treating anaemia
US9428578B2 (en) 2014-07-15 2016-08-30 Kymab Limited Methods of treating anaemia
US9439963B2 (en) 2014-07-15 2016-09-13 Kymab Limited Methods of treating anaemia
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R

Also Published As

Publication number Publication date
AU2001280471A1 (en) 2002-02-25
EP1309614A2 (en) 2003-05-14
WO2002014358A2 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
WO2002014358A3 (en) Novel secreted proteins and their uses
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
WO1999031236A3 (en) EXTENDED cDNAs FOR SECRETED PROTEINS
WO1999025825A3 (en) EXTENDED cDNAs FOR SECRETED PROTEINS
WO2001000806A3 (en) Dna's encoding proteins with signal peptides
WO2002059315A3 (en) Human nucleic acids and polypeptides and methods of use thereof
WO2001032882A3 (en) Nucleic acids and proteins from group b streptococcus
WO2002032939A3 (en) Secreted proteins and their uses
WO2001087978A3 (en) Human abc transporter and its use
WO2002026801A3 (en) Secreted proteins and their uses
WO2002048361A3 (en) Novel secreted proteins and their uses
WO2001092493A3 (en) 21956 and 25856, human aminopeptidases and uses thereof
WO2002016578A3 (en) Secreted proteins and methods of using same
WO2003012121A3 (en) Collagen xxii, a novel human collagen and uses thereof
WO2002012475A3 (en) C1q-related factor, homologous polypeptides and therapeutic uses thereof
WO2002090500A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
EP1529843A3 (en) Novel secreted proteins and their uses
WO2003029778A3 (en) Novel secreted proteins and their uses
WO2002074960A3 (en) 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof
WO2004013281A3 (en) Novel proteins and their uses
WO2003083048A3 (en) Novel secreted proteins and their uses
WO2002048187A3 (en) Secretion signal peptides, their dna sequences, expression vectors for eukaryotic cells that can be produced with the same, and use thereof for biotechnological production of proteins
WO2002046408A3 (en) Human proteins, polynucleotides encoding them and methods of using the same
WO2002081629A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
WO2004044126A3 (en) Novel proteins and their uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10343348

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001958861

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001958861

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001958861

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP